← Azimuth Daily
Capturing data…
Capturing data…
SUN, 18 OCT · 101 ITEMS
"New drug reverses severe fatty liver disease by repairing the gut" — Science Daily (all) · Science & Medicine
This is a preclinical research story: an experimental drug, DT-109, reportedly reverses (steatohepatitis) in animal models by repairing the gut barrier. The idea is that a damaged gut lets microbial products reach the liver and fuel inflammation and scarring; the drug appears to restore the barrier and thereby reduce liver injury. The headline’s “reverses” refers to results in animal models, not an approved or proven human treatment.
The claim is solid as a statement of what the underlying study reports, since the provenance is the primary paper/release itself rather than a journalist’s paraphrase. The key caveat is translational: the findings are from experimental animal models, so efficacy in humans is not yet established.
No recirculation year is given, so this is being treated as current news, though the same DT-109 finding already appeared in our July 12, 2026 digest, meaning today’s item may be another outlet writing up the same study rather than a brand-new discovery.
We covered this same study on 2026-07-12, when it was reported that the experimental drug DT-109 reverses severe fatty liver disease by repairing the gut; the microplastics item from 2026-10-12 is a separate line of research on fatty liver risk, not this same drug story.